HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increased respiratory chemosensitivity induced by oral almitrine in healthy man.

Abstract
Cardiorespiratory effects of 50 mg and 100 mg doses of almitrine and placebo given orally on separate test days to twelve healthy volunteers were assessed in a double-blind crossover study. The drug caused no significant changes in ventilation, mixed venous CO2 tension, metabolic rate, heart rate or blood pressure while they were resting and breathing room air. With progressive hypercapnia, however, the ventilatory response increased by 5% after the 50 mg dose (NS) and by 27% after the 100 mg dose (P less than 0.05). There were greater increases in the response to progressive hypoxia by 78% after 50 mg of almitrine (P less than 0.01) and by 120% after 100 mg (P less than 0.01), which was also significantly greater than the increase after the 50 mg dose (P less than 0.01). In contrast there were only minor and inconsistent changes in chemosensitivity after administering placebo. The findings are consistent with an agonist action of almitrine in the peripheral chemoreceptors and suggest that it may have clinical value in managing respiratory failure due to hypoventilation.
AuthorsN N Stanley, J M Galloway, K C Flint, D B Campbell
JournalBritish journal of diseases of the chest (Br J Dis Chest) Vol. 77 Issue 2 Pg. 136-46 (Apr 1983) ISSN: 0007-0971 [Print] England
PMID6871083 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Piperazines
  • Almitrine
Topics
  • Administration, Oral
  • Adult
  • Almitrine
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Hypercapnia (physiopathology)
  • Hypoxia (physiopathology)
  • Male
  • Piperazines (blood, pharmacology)
  • Respiration (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: